Loomis, Sayles & Company
NVCR icon

Loomis, Sayles & Company’s NovoCure NVCR Stock Holding History

Loomis, Sayles & Company’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-90
Closed -$12K – 883
2021
Q1 		$12K Sell
90
-7
-7% -$1.11K ﹤0.01% 736
2020
Q4 		$17K Buy
+97
New +$13.3K ﹤0.01% 641
2018
Q4 		– Sell
-701,565
Closed -$36.8M – 900
2018
Q3 		$36.8M Sell
701,565
-80,289
-10% -$3.2M 0.07% 115
2018
Q2 		$24.5M Buy
781,854
+10,257
+1% +$285K 0.05% 205
2018
Q1 		$16.8M Buy
+771,597
New +$16.6M 0.04% 292

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company's NVCR Position: Q2 2021 in Review

Loomis, Sayles & Company sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 90 shares — an estimated $12K sold.

Loomis, Sayles & Company first reported a position in NVCR in Q1 2018 and held it in 5 quarters. The position peaked at $36.8M in Q3 2018. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Loomis, Sayles & Company reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 90 NovoCure shares in Q2 2021, an estimated $12K.
  • Loomis, Sayles & Company first reported a position in NovoCure in Q1 2018 and held it in 5 quarters.
  • Loomis, Sayles & Company's NovoCure position peaked at $36.8M in Q3 2018.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.